Welcome to visit Zhongnan Medical Journal Press Series journal website!
Zhongnan Medical Journal Press Series of Journals Center for Evidence-Based and Translational Medicine of Wuhan University

The title
  • The title
  • The keywords
  • The author
Submit中文版

HomeArticlesVol 30,2020 No.6Detail

Evidence-based clinical practice guideline for chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19 : evidence evaluation (1)

Published on Dec. 05, 2020Total Views: 15306 timesTotal Downloads: 1592 timesDownloadMobile

Author: Ming-Zhen LI 1 Xia-Mei XU 2 Shao-Hua HE 1 Mei-Hua SHEN 3 Ying-Hui JIN 1, 4* Li-Ming TAN 5*

Affiliation: 1. Precision Medicine Centre, the Second People’s Hospital of Huaihua, Huaihua 418000, Hunan Province, China 2. Department of Intensive Care Unit, the Second People’s Hospital of Huaihua, Huaihua 418000, Hunan Province, China 3. Department of Respiratory Medicine, the Second People’s Hospital of Huaihua, Huaihua 418000, Hunan Province, China 4. Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 5. Department of Clinical Pharmacy, the Second People’s Hospital of Huaihua, Huaihua 418000, Hunan Province, China

Keywords: COVID-19 Methodology quality Overview of systematic review

DOI: 10.12173/j.issn.1004-5511.2020.06.04

Reference: Li MZ, Xu XM, He SH, Shen MH, Jin YH, Tan LM. Evidence-based clinical practice guideline for chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: Evidence evaluation (1)[J]. Yixue Xinzhi Zazhi, 2020, 30(6): 442-448. DOI: 10.12173/j.issn.1004-5511.2020.06.04.[Article in Chinese]

  • Abstract
  • Full-text
  • References
Abstract

Objective  To re-evaluate the systematic evaluation of the evidence included in the team's published clinical practice guidelines for COVID-19 drug prevention, diagnosis, treatment, and discharge management. 

Methods  we were electronically searched to collect systematic evaluation/meta-analysis of covid-19 treatment form PubMed, The Cochrane Library, Embase, CNKI and WanFang databases, and important medical journals, preprinted platform and clinical trial registry. The retrieval time was December 1, 2019 to July 8, 2020.AMSTAR 2 tool was used to evaluate the methodological quality of the included system evaluation. 

Results  A total of 6 systematic evaluations/meta-analyses were included, four were drug therapy and two were immunotherapy. The evaluation results of AMSTAR 2 showed that the methodological quality of 1 study was high, 3 were medium, 1 was low, and 1 was extremely low. Methodology deficiencies are mainly reflected in the scheme and registration, analysis methods and funding sources, and so on. 

Conclusions  The methodological quality of the systematic evaluation of COVID-19 treatment is extremely low to high, and some conclusions cannot be determined. High-quality studies with large samples and long-term follow-up are still needed to confirm this.

Full-text
Please download the PDF version to read the full text: download
References

1. Abduljalil JM, Abduljalil BM. Epidemiology, genome,and clinical features of the pandemic SARS-CoV-2: a recent view[J]. New Microbes New Infect, 2020, 35: 100672. DOI: 10.1016/j.nmni. 2020.100672.

2. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard[EB/OL]. World Health Organization. 2020. [2020-10-31]. https://covid19.who.int/.

3. Schünemann H J, Hill S R, Kakad M, et al. Transparent development of the WHO rapid advice guidelines[J]. PLoS Med, 2007, 4(5): e119. DOI: 10.1371/journal.pmed. 0040119.

4. Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)[J]. Military Medical Research, 2020, 7(1): 4. DOI: 10.1186/s40779-020-0233-6.

5. 靳英辉,詹庆元,彭志勇,等.新型冠状病毒肺炎药物预防、诊断、治疗与出院管理循证临床实践指南(更新版)[J].解放军医学杂志, 2020, 45(10): 1003-1031. DOI: 10.11855/j.issn.0577-7402. [Jin YH, Zhan QY, Peng ZY,et al. Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline(updated version)[J]. Medical Journal of Chinese People's Liberation Army, 2020, 45(10): 1003-1031.]

6. Jin YH, Zhan QY, Peng ZY, et al. Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline(updated version)[J]. 2020, Mil Med Res, 2020, 7(1): 41. DOI: 10.1186/s40779-020-00270-8.

7. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both[J]. BMJ, 2017, 358: j4008. DOI: 10.1136/bmj.j4008.

8. 张方园,沈傲梅,曾宪涛,等.系统评价方法学质量评价工具AMSTAR2解读[J].中国循证心血管医学杂志, 2018, 10(1): 14-18. DOI: 10.3969/j.issn.1674-4055. 2018.01.03. [Zhang FY, Shen AM, Zeng XT, et al. An Introduction to AMSTAR 2: a critical appraisal tool for systematic reviews[J]. Chin J Evid Based Cardiovasc Med, January, 2018, 10(1): 14-18.]

9. Elavarasi A, Prasad M, Seth T, et al. Chloroquine and Hydroxychloroquine for the treatment of COVID-19: A Systematic Review and Meta-analysis[J]. J Gen Intern Med, 2020, 3: 1-7. DOI: 10. 1007/s11606-020-06146-w.

10.    Roshanshad A, Kamalipour A, Ashraf MA, et al. Remdesivir Efficacy in Coronavirus Disease 2019 (COVID-19): A Systematic Review[J]. medRxiv, 2020.06.15.20131227. DOI: 10.1101/2020.06.15.20131227.

11.    Hernandez AV, Roman YM, Pasupuleti V, et al. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review[J]. Ann Intern Med, 2020, 173(4): 287-296. DOI: 10.7326/M20 -2496.

12.    Boregowda U, Perisetti A, Nanjappa A, et al. Addition of Tocilizumab to the standard of care reduces mortality in severe COVID-19: A systematic review and meta-analysis[J]. Frontiers in Medicine, 2020, 7: 586221. DOI: 10.3389/fmed.2020.586221.

13.    Singh AK, Majumdar S, Singh R, et al. Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective[J]. Diabetes Metab Syndr, 2020, 14(5): 971-978. DOI: 10.1016/j.dsx.2020.06.054.

14.    Piechotta V, Chai KL, Valk SJ, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review[J]. Cochrane Database Syst Rev, 2020, 7(7): Cd013600. DOI: 10.1002/14651858.CD013600.pub2.

15.    贾秀玲, 李棒棒, 孙忠华, 等.新型冠状病毒感染及新型冠状病毒肺炎治疗药物研究进展[J].山东医药，2020, 60(9): 108-112. DOI: 10.3969/ j.issn.1002-266X.2020.09.029. [Jia XL, Li BB, Sun ZH, et al. Research Progress of COVID-19 infection and drug therapeutics[J]. Shandong Med, 2020, 60(9): 108-112.]

16.    Bauchner H, Fontanarosa PB. Randomized Clinical Trials and COVID-19: Managing Expectations[J]. JAMA, 2020, 323(22): 2262-2263. DOI: 10.1001/jama.2020.8115.

17.    Cao B, Wang YM, Wen DN, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19[J]. N Engl J Med, 2020, 382(19): 1787-1799. DOI: 10.1056/NEJMoa2001282.

18.    Li YP, Xie ZW, Lin WY, et al. An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI)[J]. medRxiv, 2020.DOI: 10.1101/2020.03.19.20038984.

19.    Pereda R, Gonzalez D, Rivero HB, et al. Therapeutic effectiveness of interferon-alpha2b against COVID-19: the Cuban experience[J]. J Interferon Cytokine Res, 2020, 40(9): 438-442. DOI: 10.1089/jir.2020.0124.

20.    Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19-Final Report[J]. N Engl J Med, 2020, NEJMoa2007764. DOI: 10.1056/NEJMoa2007764.

21. National Institute of Health. Coronavirus disease 2019(COVID-19) treatment guidelines [EB/OL]. (2020-10-9) [2020-11-1]https://www.covid19treatmentguidelines.nih.gov/.

22.    澎湃新闻.瑞德西韦获FDA正式授权，成为全美首个获批新冠治疗药物[EB/OL].(2020-10-23)[2020-11-1] https://www.thepaper.cn/newsDetail_forward_9696502.

23.    国家卫生健康委员会.新型冠状病毒肺炎诊疗方案（试行第八版）[EB/OL]. (2020-08-19) [2020-11-1]www.nhc.gov.cn/xcs/zhengcwj/202008/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a.shtml.

Popular Papers
© 2022 - 2024 Zhongnan Medical Journal Press of Zhongnan Hospital of Wuhan University|Support: Yufu Technology
About NM | Contact us